Vaccine

Abstract

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form Streptococcus pneumoniae , and optionally a Th1-inducing adjuvant.

1 - 15 . (canceled)  
     
     
         16 . An immunogenic composition comprising at least one  Streptococcus pneumoniae  polysaccharide-protein conjugate, with at least one unconjugated  Streptococcus pneumoniae  protein antigen, and an adjuvant which is a preferential inducer of a TH1 response.  
     
     
         17 . The immunogenic composition of  claim 16 , wherein the unconjugated  Streptococcus pneumoniae  protein antigen is an outer surface protein or a secreted protein of  Streptococcus pneumoniae.    
     
     
         18 . The immunogenic composition of  claim 16 , wherein the unconjugated  Streptococcus pneumoniae  protein antigen is a toxin, adhesion or lipoprotein of  Streptococcus pneumoniae.    
     
     
         19 . The immunogenic composition of  claim 16 , wherein the unconjugated  Streptococcus pneumoniae  protein antigen is selected from the group consisting of: pneumolysin, PspA, PspC, PsaA, glyceraldehyde-3-phosphate dehydrogenase, and CbpA.  
     
     
         20 . The immunogenic composition of  claim 16 , wherein the protein carrier in the polysaccharide-protein conjugate is selected from the group consisting of: Diphtheria toxoid, Tetanus toxoid, CRM197, Keyhole Limpet Haemocyanin (KLH), protein derivative of Tuberculin (PPD), and protein D from  H. influenzae.    
     
     
         21 . An immunogenic composition of  claim 16  which comprises at least four pneumococcal polysaccharide antigens from different serotypes.  
     
     
         22 . An immunogenic composition as claimed in  claim 16 , wherein the adjuvant comprises at least one of the following: 3D-MPL, a saponin immunostimulant, or an immunostimulatory CpG oligonucleotide.  
     
     
         23 . An immunogenic composition as claimed in  claim 22 , wherein the adjuvant comprises a carrier selected from the group consisting of: an oil in water emulsion, liposomes, and an aluminium salt.  
     
     
         24 . A vaccine comprising the immunogenic composition of any one of claims  16 - 23 .